AR041476A1 - Uso de antagonistas de receptores 5-ht2 - Google Patents

Uso de antagonistas de receptores 5-ht2

Info

Publication number
AR041476A1
AR041476A1 ARP030103600A ARP030103600A AR041476A1 AR 041476 A1 AR041476 A1 AR 041476A1 AR P030103600 A ARP030103600 A AR P030103600A AR P030103600 A ARP030103600 A AR P030103600A AR 041476 A1 AR041476 A1 AR 041476A1
Authority
AR
Argentina
Prior art keywords
rem
fluorofenetyl
piperazin
prolong
drug
Prior art date
Application number
ARP030103600A
Other languages
English (en)
Inventor
Bartoszyk Gerd Dr
Van Amsterdam Christoph Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32010223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041476(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR041476A1 publication Critical patent/AR041476A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Uso de antagonistas de receptores 5-HT2 para preparar un medicamento para prolongar tanto el sueno no REM como el sueno REM. Reivindicación 3: Uso de antagonistas de receptores 5-HT2a, seleccionados de un grupo integrado por: a) (3-aminocarbonil-1H-indol-7-il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona; b) (3-cian-1H-indol-7-il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona, así como sus sales y solvatos de tolerancia fisiológica para preparar un medicamento para prolongar tanto el sueno no REM como también el sueno REM.
ARP030103600A 2002-10-04 2003-10-03 Uso de antagonistas de receptores 5-ht2 AR041476A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10246357A DE10246357A1 (de) 2002-10-04 2002-10-04 Verwendung von 5-HT2Rezeptorantagonisten

Publications (1)

Publication Number Publication Date
AR041476A1 true AR041476A1 (es) 2005-05-18

Family

ID=32010223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103600A AR041476A1 (es) 2002-10-04 2003-10-03 Uso de antagonistas de receptores 5-ht2

Country Status (18)

Country Link
US (1) US20060040951A1 (es)
EP (1) EP1545531A1 (es)
JP (1) JP2006503870A (es)
KR (1) KR20050054996A (es)
CN (1) CN1688309A (es)
AR (1) AR041476A1 (es)
AU (1) AU2003283237A1 (es)
BR (1) BR0314945A (es)
CA (1) CA2501082A1 (es)
DE (1) DE10246357A1 (es)
MX (1) MXPA05003437A (es)
PE (1) PE20040569A1 (es)
PL (1) PL374077A1 (es)
RU (1) RU2005113712A (es)
TW (1) TW200410691A (es)
UA (1) UA79993C2 (es)
WO (1) WO2004032932A1 (es)
ZA (1) ZA200503520B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004047517A1 (de) * 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865939A (en) * 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
DE3119383A1 (de) * 1981-05-15 1982-12-02 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
DE60004479T2 (de) * 1999-02-03 2004-06-24 Forbes Medi-Tech Inc., Vancouver Verfahren zur herstellung von phytosterol- oder phytostanol-mikropartikeln
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US6391370B1 (en) * 1999-11-12 2002-05-21 Kraft Foods, Inc. Micromilling plant sterols and emulsifiers
US6576285B1 (en) * 2000-11-14 2003-06-10 Sunpure Ltd. Cholesterol lowering beverage
DE10102944A1 (de) * 2001-01-23 2002-07-25 Merck Patent Gmbh Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten

Also Published As

Publication number Publication date
RU2005113712A (ru) 2005-11-20
EP1545531A1 (de) 2005-06-29
TW200410691A (en) 2004-07-01
BR0314945A (pt) 2005-08-02
UA79993C2 (en) 2007-08-10
ZA200503520B (en) 2006-02-22
PE20040569A1 (es) 2004-08-30
MXPA05003437A (es) 2005-07-05
CA2501082A1 (en) 2004-04-22
KR20050054996A (ko) 2005-06-10
CN1688309A (zh) 2005-10-26
AU2003283237A1 (en) 2004-05-04
JP2006503870A (ja) 2006-02-02
WO2004032932A1 (de) 2004-04-22
US20060040951A1 (en) 2006-02-23
DE10246357A1 (de) 2004-04-15
PL374077A1 (en) 2005-09-19

Similar Documents

Publication Publication Date Title
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
ECSP034640A (es) Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
AR035722A1 (es) Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la produccion de medicamentos
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
DK1175401T3 (da) Piperazinderivater, der er nyttige som CCR5-antagonister
GT200100160A (es) Derivados 4-fenil-piridina.
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
UY26291A1 (es) Compuestos químicos xxii
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
AR058670A1 (es) Ciclopropil aminas como moduladores del receptor h3 de histamina. composiciones farmaceuticas
ATE308522T1 (de) Opioidrezeptorantagonisten
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
AR041476A1 (es) Uso de antagonistas de receptores 5-ht2
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
AR025990A1 (es) Uso de derivados de carbonilamino para el tratamiento de enfermedades relacionadas con el sistema.
AR044713A1 (es) Derivados de indol como inhibidores de la recaptacion de serotonina
ATE400568T1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten
UY29733A1 (es) Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotrópicos
ECSP088236A (es) Formas y composiciones de dosificaciones farmacéuticas
MXPA05005340A (es) Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal